key: cord-0329960-8i7v0f97
authors: Ritchie, S. C.; Surendran, P.; Karthikeyan, S.; Lambert, S. A.; Bolton, T.; Pennells, L.; Danesh, J.; Di Angelantonio, E.; Butterworth, A. S.; Inouye, M.
title: Quality control and removal of technical variation of NMR metabolic biomarker data in ~120,000 UK Biobank participants
date: 2021-09-27
journal: nan
DOI: 10.1101/2021.09.24.21264079
sha: e73412fe9230f88044907653c4e2572e69fbb8f3
doc_id: 329960
cord_uid: 8i7v0f97

Metabolic biomarker data quantified by nuclear magnetic resonance (NMR) spectroscopy for 249 circulating metabolites, lipids, and lipoprotein sub-fractions has recently become available in UK Biobank for approximately 121,657 participants. Here, we describe procedures for quality control and removal of technical variation for this biomarker data. We show that technical and biological effects with linear effects on individual biomarkers can combine in a non-linear fashion on (the 61) composite biomarkers and (81) biomarker ratios, and thus composite biomarkers and ratios should be re-derived after removal of unwanted variation to avoid introducing such cryptic effects. We make available an R package, ukbnmr, for extracting the metabolic biomarker data from UK Biobank and removing the unwanted technical variation. We also make available code for re-deriving the 61 composite biomarkers and 81 ratios, and for further derivation of 76 additional biomarker ratios of potential biological significance. Finally, we demonstrate that our removal of technical variation leads to increased signal for genetic and epidemiological studies of the NMR metabolic biomarkers in UK Biobank.

Metabolic biomarker data quantified by nuclear magnetic resonance (NMR) spectroscopy for 249 24 circulating metabolites, lipids, and lipoprotein sub-fractions has recently become available in UK Biobank  25 for approximately 121,657 participants. Here, we describe procedures for quality control and removal of 26 technical variation for this biomarker data. We show that technical and biological effects with linear 27 effects on individual biomarkers can combine in a non-linear fashion on (the 61) composite biomarkers 28 and (81) biomarker ratios, and thus composite biomarkers and ratios should be re-derived after removal of 29 unwanted variation to avoid introducing such cryptic effects. We make available an R package, ukbnmr, 30

for extracting the metabolic biomarker data from UK Biobank and removing the unwanted technical 31 variation. We also make available code for re-deriving the 61 composite biomarkers and 81 ratios, and for 32 further derivation of 76 additional biomarker ratios of potential biological significance. Finally, we 33 demonstrate that our removal of technical variation leads to increased signal for genetic and 34 epidemiological studies of the NMR metabolic biomarkers in UK Biobank. 35

Introduction 36 High-throughput NMR spectroscopy has enabled rapid simultaneous quantification of lipids, lipoproteins, 37 fatty acids, and low-molecular weight metabolites including amino acids, ketone bodies, and glycolysis 38 metabolites from a single human blood plasma sample (Ala-Korpela et al., 2021; Würtz et al., 2017) . Over 39 the last decade, NMR metabolic biomarker data has been quantified in numerous cohorts each with 40 thousands participants, helping derive new insights into the epidemiology and molecular pathogenesis of 41 cardiovascular and metabolic diseases and examine the genetic determinants of these molecular risk 42 factors and disease biomarkers (Soininen et al., 2015) . 43

The emergence and increasing scale of biobanks containing hundreds of thousands to millions of samples 44

promises to enable discovery of new insights into human health and disease. To date, biomarker 45 quantification has been completed in 121,695 participants (Julkunen et al., 2021) , which have recently 46 been made available for download by UK Biobank. Molecular phenotype data in large sample sizes are 47 typically subject to the effects of unwanted technical variation (e.g. batch effects) which can obscure true 48 biological effects and/or introduce false positive associations. Thus, a typical first step in any analysis is 49

to identify and remove sources of unwanted variation from raw data. Here, we report additional quality 50 control (QC) procedures to remove effects of technical variation on biomarker concentrations, which we 51 make available as a resource to the community via an R package, ukbnmr. 52 include fatty acids, amino acids, ketone bodies, glycolysis related metabolites, and others. An overview of 62 available biomarkers and ratios are provided in Figure 1 , and details are provided in Table S1 . 63

There were 22 (of 249) biomarkers with at least 5% of variance explained by one or more technical 73 factors, with strongest impacts observed for inter-spectrometer differences in biomarker concentrations, 74 along with drift over time across different plates measured within each spectrometer ( Figure 2B ). 75 Notably, 33% of the variance in alanine concentrations could be explained by drift over time within 76 spectrometer ( Figure 2B , Figure 3A ) followed by 15% of the variance in histidine concentrations which 77 could be explained by time between sample preparation and sample measurement ( Figure 2B , Figure  78 3B). Further, inter-spectrometer differences in biomarker concentrations and drift over time within 79 spectrometer were visually apparent for nearly all biomarkers (see extended diagnostic plots; Data 80 Availability). Intra-plate variation was also visually apparent for some biomarkers (extended diagnostic 81 plots; Data Availability), for example, we observed a consistent decrease in glycine concentrations from 82 left to right across each plate ( Figure 3C ). 83 84 Technical variation was subsequently removed using a multistep pipeline (Methods) detailed below. 85 Figure 4 gives a step-by-step example, for the NMR amino acid glycine, showing how concentrations and 86 their relationship with technical covariates changes at each step. 87

A key motivating consideration at each step was to ensure adjustment for categorical technical factors did 88 not break the samples into very small groups with potential to be non-random with respect to biological 89 factors. For example, a simple approach to remove inter-plate variation would be to median normalise 90 each plate. However, with only 94 samples measured per plate, this approach would likely remove not just 91 technical variation but also biological variation of interest to downstream analysts. For example, 92

allocation of participants to plates were not randomised with respect to participant sex ( Figure S1 ), thus 93

per-plate normalization would remove some sex-specific differences in metabolite concentrations, which 94 may be of interest to downstream researchers. 95

With this consideration in mind, technical variation was removed through four sequential regressions 96 (Methods). First, (1) biomarkers were regressed on time between sample preparation and sample 97 measurement to remove any potential effects of sample degradation ( Figure 4C ). Next, (2) subsequent 98 residuals were regressed on plate row (8 groups; rows A-H; Figure 4D ) as visual differences between 99 plate rows remained after removing effects of sample degradation time ( Figure 4C ). Third, (3) 100 subsequent residuals were regressed on plate column (12 groups; columns 1-12; Figure 4E ) as 101 differences between plate columns were apparent for some biomarkers ( Figure S2 ). Finally, (4) inter-102

plate variation due to drift over time within spectrometer was removed ( Figure 4F ) by binning plates into 103 10 groups by date within each of the 6 spectrometers ( Figure S3 ) and regressing on bin as a categorical 104

variable. At each of these steps robust linear regression (Methods) was used to fit robust linear 105 regressions as we found linear regression susceptible to outliers and non-normality ( Figure S4) . 106

Prior to fitting these regressions, biomarker concentrations were log transformed ( Figure 4B ) so that a 107 unit decrease in biomarker levels were equivalent to a unit increase (e.g. a halving and doubling both 108 become a 0.69 unit change on the natural log scale). A small offset was applied for biomarkers with 109 concentrations of 0 (Table S3) . Subsequent to regressing out effects of technical variation, absolute 110 biomarker concentrations were obtained ( Figure 4G ) from the regression residuals by rescaling their 111 distribution to the raw data (Methods, Figure S5 ). 112 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint After removing most visible inter-plate variation ( Figure 4F-G) , we observed for many biomarkers 113 several strong outlier plates (extended diagnostic plots; Data Availability) . The strongest example, for  114 albumin concentrations, is shown in Figure 5A . Stratification of albumin concentrations previously  115  quantified by clinical biochemistry (Allen et al., 2020) according to the UK Biobank shipping plates used  116  to send samples for NMR metabolite quantification supported a non-biological origin for the observed  117 outlier plates ( Figure 5B ). Investigation of control samples placed on each plate by Nightingale Health 118

Plc. to assess the NMR quantification process showed no deviation of control samples for outlier plates 119 (Figure 5C ), indicating the source of this technical variation was not due to the NMR quantification 120 pipeline rather arose during the UK Biobank sample plating process. However, these outlier plates could 121 not be adjusted for using any of the available technical covariates detailed in Figure 2A . We therefore 122 systematically identified and removed these outlier plates (Methods) as the final step in the pipeline to 123 remove unwanted technical variation ( Figure 4H ). Across biomarkers, these accounted for a median of 9 124 plates (0.66% of plates/samples), with maximum of 20 plates (1.5% plates/samples) for albumin and 125

phosphoglycerides. 126

Among the 249 NMR metabolite biomarkers available to download from UK Biobank, 81 were derived 128 ratios, 61 were composite biomarkers, derivable as sums of two or more biomarkers (Figure S6) , and 107 129

were non-derivable from other biomarkers (Figure 1 , Table S1, Table S2 ). 130

Notably, we found that directly adjusting composite biomarkers or biomarker ratios for technical 131 covariates sometimes led to different post-QC concentrations or ratios than obtained by computing the 132 biomarker from its adjusted composite parts ( Figure 6A ). In particular, technical covariates could have 133 different or even opposing effects on biomarkers contributing to a composite biomarker (Figure 6B) , 134 which could combine in a non-linear fashion on the composite biomarker ( Figure 6C ). These differences 135 are proportional to the effects of the adjusted covariates on each biomarker: we highlight that these 136 differences are much larger when adjusting for age, sex, and body mass index (BMI) (Figure 6D ), which 137 have much larger impacts on biomarker concentrations than technical covariates ( Figure 6E ). 138

When removing the effects of technical variation above, we therefore recomputed the 61 composite 139 biomarkers and 81 biomarker ratios after removing the effects of technical covariates from the 107 non-140 derivable biomarkers. We make available code for re-deriving these biomarkers and ratios in the ukbnmr 141 R package (Code Availability). 142 143 We further derived 76 additional biomarker ratios not available in the original data (Figure 1 , free cholesterol, (4) cholesteryl esters, and (5) total cholesterol (Figure 1) . Here, we additionally derive 150 these percentages for the three lipoprotein classes: very low density lipoprotein (VLDL), low density 151 lipoprotein (LDL), and high density lipoprotein (HDL), as well as for total lipids in serum (Figure 1) . 152 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 27, 2021. ; https://doi.org/10.1101/2021.09.24.21264079 doi: medRxiv preprint Next, we note that total cholesterol is composed of the sum of free cholesterol and esterified cholesterol 153 (Table S2) , thus derive cholesterol fractions (percentages of cholesterol made up of free cholesterol and 154 esterified cholesterol) for total serum, the three lipoprotein classes, and 14 lipoprotein sub-classes ( Figure  155 1). We also derived the ratio of free cholesterol to cholesteryl esters as there is some evidence that this 156 ratio may be a determinant of lipoprotein atherogenicity (Bagheri et al., 2018) . 157

Finally, we note that polyunsaturated fatty acids are composed of the sum of omega-3 and omega-6 fatty 158 acids (Table S2) , thus derive the percentage of polyunsaturated fatty acids comprised of omega-3 and 159 omega-6 fatty acids (Figure 1) . 160

Next, we examined whether removal of technical variation impacted or improved power for genetic and 162 epidemiological studies (Methods). 163

We performed genome-wide association analyses (GWAS) (Methods) for raw and post-QC 164

concentrations of alanine, the biomarker most strongly affected by technical variation (Figure 2B) , and 165 albumin, the biomarker most strongly impacted by outlier plates (Figure 5A ). We observed an increase in 166 power for genetic associations for both biomarkers when using their post-QC concentrations with 167 technical variation removed ( Figure 7A , Figure S7 , Table S4 ). 168 A comparatively modest difference in power was observed for biomarker association scans in Cox 169

proportional hazards models for incident coronary artery disease and incident stroke (Methods, Figure  170 7B, Table S5 ). However, large differences in power are not expected in a biomarker association unless 171 the biomarkers most strongly associated with the disease are also the ones most strongly impacted by 172 technical variation. Notably, a large increase in power was observed for the association between albumin 173 concentrations and incident stroke, which became the strongest association among the 249 biomarkers 174 after removal of technical variation ( Figure 7B ). 175

We also observed strong associations between the 76 additional biomarker ratios derived above with 176 incident disease (Table S5) , supporting their utility for future studies. For example, the percentage of 177 LDL lipids composed of cholesterol was the biomarker with the strongest association with stroke (hazard 178 ratio: 0.89, 95% confidence interval: 0.86-0.91, P-value: 2×10 −15 ) above and beyond that of albumin (HR: 179 0.83, 95% CI: 0.79-0.87, P-value: 5×10 −13 ). 180

Finally, we explore and describe basic characteristics of the post-QC data of fundamental interest to 182 downstream analysts in Figure 8 . Specifically percentages of missing data across biomarkers ( Figure 8A ) 183 and samples (Figure 8B ), correlation between biomarkers (Figure 8C) , and sources of inter-sample 184 variation due to common physiological and environmental confounders (Figure 8D-F) . In particular, we 185

highlight that approximately 30% of the variation between biomarkers can be explained by a combination 186 of sex, body mass index (BMI), and lipid lowering medication usage (Figure 8E) , and that clustering of 187 male and female participants is visible on PC1 and PC3 ( Figure 8F , Figure S8 ). We also highlight that 188 the structure of the data and relationships between biomarkers are largely unchanged from the raw data 189

( Figure S9) , with the exception of biomarker and sample missingness rates which are higher in the post-190 QC data (Figure 8A -B) due to the removal of outlier plates arising from unexplained technical variation 191 ( Figure 5) . 192 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 27, 2021. ; https://doi.org/10.1101/2021.09.24.21264079 doi: medRxiv preprint

Technical variation is inherent to all laboratory measurements used for molecular phenotyping at biobank 194 scale. Here, we comprehensively explored and document the sources and impacts of technical variation on 195 the NMR metabolite biomarker data for ~120,000 UK Biobank participants. We found that the vast 196 majority of biomarkers are relatively robust to technical variation, but that a small subset are significantly 197 impacted by inter-spectrometer variation, within-spectrometer drift over time, and intra-plate variation. 198 We also found that a small number of plates are unexplained outliers of non-biological origin across a 199 swathe of biomarkers. We subsequently developed a multi-step procedure for removing this unwanted 200 variation, which we make available as part of the ukbnmr R package as a resource to the community. 201

We additionally highlight several important aspects of the NMR metabolite biomarker data analysts 202

should be aware of. 203

First, there are major sources of biological variation that have systematic effects on biomarker 204

concentrations between individuals. These include major differences in most biomarker concentrations 205 depending on participant sex, body mass index, and use of lipid lowering medication, which are expected 206 due to the predominantly lipid content of the biomarker data. 207

We also highlight the strong correlation structure between biomarkers, particularly among lipid 208

concentrations, which are typical property for this type of data ( epidemiological and genetic studies for the NMR metabolic biomarkers more broadly. We would also 217 highlight that filtering to non-derived biomarkers does not mitigate challenges introduced by collinearity, 218 as many of the non-derived biomarkers are among those with extremely strong inter-correlations. 219

Analysts should also be aware that no filtering or treatment of outlier samples is performed by the ukbnmr 220 R package when removing technical variation. Many biomarkers have extreme outliers whose treatment 221 will need to be carefully considered for statistical modelling and many biomarkers have extremely non-222 normal distributions. One approach to handle these can be to winsorize biomarker distributions (either 223 before or after log transformation) or to inverse rank normalize them. 224

Further, analysts should also be aware that Nightingale Health Plc has flagged some non-missing samples 225 and For some analysts, the post-QC dataset generated by our code in the ukbnmr R package may simply be a 232

starting point for creating their own quality controlled datasets with further adjustment for unwanted 233 biological variation, for example adjusting for age and sex for downstream GWAS. For these, we 234 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint In conclusion, we envision this manuscript and methods made available for removing technical variation 241

in the ukbnmr R package will serve as a useful starting point for those who wish to use the NMR 242 metabolite biomarker data available for ~120,000 UK Biobank participants in their future studies. 243 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 10 cores on high performance computing cluster). 305

Raw biomarker data was filtered to 107 "non-derived" biomarkers: biomarkers that could not be 307 expressed in terms of two or more other quantified biomarkers ( Table S1, Table S2 ). Concentrations of 308 these biomarkers were log transformed, with a small offset applied to biomarkers with 0 values (half the 309 minimum non-zero value; Table S3 ). 310

Four sequential regressions were fit to remove the effects of known technical covariates (Figure 4) Figure S3 ). 328

After removing the effects of known technical covariates from the 107 non-derived biomarkers, their 330 residuals were converted back to absolute concentrations through the procedure described below (Figure  331 S5). 332

The residuals from any regression are defined as the difference between the observed independent 333

variable (e.g. biomarker concentrations) and the parameter estimated by the regression. A resulting key 334

property is that the distribution of the residuals is centred on 0 for this estimated parameter. In the case of 335 robust linear regression, this parameter is an estimate of the mean that is robust to outliers (Huber, 2004; 336 Venables and Ripley, 2002). As a consequence of the way residuals are defined, their distribution can be 337 scaled to match the distribution of the independent variable by giving it the same estimated mean. For 338 robust linear regression, residuals can be returned to the same scale as the observed independent variable 339 by estimating the mean of the observed independent variable using robust linear regression and adding it 340

to the residuals. 341

When adjusting for technical covariates above, the independent variable was the log transformed raw 342

concentrations of each biomarker. For each biomarker, we therefore fit a robust linear regression on the 343 log transformed raw biomarker concentrations with just an intercept term to obtain an estimate of the 344 mean robust to outliers. We then added this estimated mean to the residuals to return the residuals to the 345 same scale as the log transformed raw concentrations. To return biomarkers to absolute concentrations, 346

instead of log-concentrations, the exponent function was applied to inverse the log transformation. For 347 biomarkers with concentrations of 0 in the raw data, the small offset applied prior to log transformation 348 (Table S3 ) was also removed. Subsequently, some samples with concentrations of 0 in the raw data had 349 negative concentrations very close to zero in the post-QC data; a small offset was applied to these 350 biomarkers to ensure no negative concentrations (Table S3 ). In all cases this offset was at least one order 351 of magnitude smaller than the smallest non-zero concentration, i.e. its impact on concentrations amounts 352 to noise in numeric precision. 353

Outlier plates were subsequently identified and removed for each of the 107 non-derived biomarkers 355

( Figure 4H, Figure 5 ). To identify outlier plates, we modelled the distribution of plate medians for each 356 biomarker as a normal distribution. For each biomarker, we computed the mean and standard deviation of 357 plate medians across the 1,352 plates. Acceptable limits for plate medians ( Figure 5A) were then set 358 based on the limits of a theoretical normal distribution of 1,352 points. Plates were subsequently flagged 359 and removed as outliers if their median concentration was greater than or less than 3.3744 standard 360 deviations of mean of the 1,352 plate medians. A non-biological origin for outlier plates was confirmed 361 by examining concentrations of biomarkers from previously quantified clinical biochemistry data (Allen 362 et al., 2020) ( Figure 5B) . 363

To create the final post-QC dataset, we subsequently recomputed the 61 composite biomarkers and 81 365 biomarker ratios available in the raw data from the 107 non-derived biomarkers using the ukbnmr R 366 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 27, 2021. Table S2 ). We also computed 76 additional biomarker ratios not 367 available in the original raw data (Figure 1, Table S1 , Table S2 ). 368

In Figure 6A -C we compared these computed post-QC biomarkers to those obtained by directly adjusting 370 the biomarker for the technical covariates as described above. When doing so, percentage biomarkers 371 (Table S1) were logit transformed rather than log transformed. 372

For Figure 6D ,E we additionally created two datasets further adjusting for age, sex, and BMI: one in 373 which the derived biomarkers were computed from the 107 non-derived biomarkers after adjustment, and 374 one in which the derived biomarkers were directly adjusted. In both cases the starting point was the post-375 QC dataset described above, and robust linear regressions were fit for each biomarker on age, sex, and log 376 transformed BMI. Post-QC biomarker concentrations were log or logit transformed as appropriate prior to 377 fitting robust linear regressions, and residuals rescaled to absolute concentrations as described above. 378

Genome-wide association studies (GWASs) were performed for raw and post-QC alanine and albumin 380

( Figure 7A , Figure S7 , 

Cox proportional hazards models were fit using the R package survival (version 3.2-7) (Therneau and 409

Grambsch, 2013) to test associations between raw and post-QC biomarker levels with incident coronary 410 artery disease and incident stroke ( Figure 7B , To ensure strong negative correlations were clustered with strong positive correlations the absolute value 443 of the pairwise Pearson correlation was taken prior to distance calculation, and a penalization exponent of 444 6 applied to shrink weak correlations towards zero as recommended in the package documentation 445 (Langfelder and Horvath, 2008) . 446

For Figure 8D-F, Figure S8 , and Figure S9D -F, principal components analysis (PCA) was performed 448 across participants. For PCA, biomarker concentrations were first either logit transformed (percentages; 449 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 27, 2021. ; https://doi.org/10.1101/2021.09.24.21264079 doi: medRxiv preprint Table S1 ) or log transformed (all other biomarkers) and standardised to have mean of 0 and unit variance. 450

Small offsets were applied to biomarkers with 0 values to facilitate log transformation, and for 451 percentages, small negative offsets were applied for those with values of 100%. Missing values were 452 imputed as the biomarker mean (0) as PCA could not handle missing data. Ratios with infinite (x/0) or 453 undefined (0/0) values were also set to missing prior to log transformation. The prcomp function in R was 454 used for PCA. 455

To identify biological correlates of fitted principal components (PCs) (Figure S8E, Figure S9E) The funders had no role in study design, data collection and analysis, decision to publish, or preparation 496 of the manuscript. The views expressed are those of the author(s) and not necessarily those of the NIHR 497 or the Department of Health and Social Care. 498 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. be derived by summing two or more of the 107 non-derived biomarkers. Shown in blue are the 595 biomarker ratios available in the raw data, which can be derived from the 168 non-derived or compo 596

biomarkers. Further details for each biomarker and ratio are provided in Table S1 and formulae  597 deriving the composite biomarkers and ratios are provided in Table S2 . 598 17 ata as ed by from at can he 81 posite ae for . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 19 Each , and ed by ng by time log 10 lycine n (1after . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (horizontal bars show the 95% confidence intervals). C) Shows the difference between total lipids in 668

HDL computed from its adjusted parts to total lipids in XL HDL directly adjusted for sample degradat 669 time (y-axis) as a function of its concentration (x-axis) with points coloured by sample degradation ti 670 (hours). D,E) Shows how large differences can arise when adjusting for biological covariates with la 671 effects on biomarker concentrations. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 27, 2021. ; https://doi.org/10.1101/2021.09.24.21264079 doi: medRxiv preprint

Sunyaev 500 SR. 2010. A method and server for predicting damaging missense mutations

Apt interpretation of 503 comprehensive lipoprotein data in large-scale epidemiology -disclosure of fundamental structural 504 and metabolic relationships. medRxiv

Approaches to minimising the epidemiological impact of sources of systematic 507 and random variation that may affect biochemistry assay data in UK Biobank

The Ratio of Unesterified/esterified Cholesterol is 510 the Major Determinant of Atherogenicity of Lipoprotein Fractions

BGEN: a binary file format for imputed genotype and haplotype data

Approximately independent linkage disequilibrium blocks in human 514 populations

Genome-517 wide genetic data on ~500,000 UK Biobank participants

The UK Biobank resource with deep phenotyping and genomic data

Second-generation PLINK: 523 rising to the challenge of larger and richer datasets

525 Statistical methods for handling unwanted variation in metabolomics data

European Organization for Nuclear Research

Robust Statistics

Novel Loci for metabolic 532 networks and multi-tissue expression studies reveal genes for atherosclerosis

Nightingale Health UK Biobank Initiative. 2021. 535 Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and 536 COVID-19 in the general population

WGCNA: an R package for weighted correlation network analysis

Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation 540 matrix

Reference-based phasing using the 543

Haplotype Reference Consortium panel

Robust relationship 545 inference in genome-wide association studies

The authors are grateful to UK Biobank for access to data to undertake this study (Projects #30418 and 480 #7439).

biomarker for each disease is annotated. Cox proportional hazard models were fit adjusting for age 697 sex. Participants with prevalent events or taking lipid lowering medication were excluded. Hazard ra 698 for all biomarkers are detailed in Table S5 . 699